Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | HK1 | P19367 | 4/20 | 0.35 |
| ▸ | HK2 | P52789 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058347 | 0.92 | PTGS2 (0.43) | PTGS2 | |
| SCHEMBL25957856 | 0.91 | ACACB (0.34) | SLC2A1PYGBACACBALDH1A1SMN1; SMN2 | |
| SCHEMBL21138772 | 0.83 | PTGS2 (0.42) | PTGS2 | |
| SCHEMBL25957583 | 0.82 | PTGS2 (0.37) | PTGS2 | |
| Hydrochloric Acid SCHEMBL31353002 | 0.80 | PYGB (0.41) | PYGBHK1HK2ALDH1A1 | |
| SCHEMBL21137980 | 0.78 | PYGB (0.40) | PYGBHK1HK2ALDH1A1SLC5A1 | |
| SCHEMBL28855878 | 0.78 | PYGB (0.40) | PYGBHK1HK2ALDH1A1SLC5A1 | |
| SCHEMBL21137857 | 0.77 | HK1 (0.41) | HK1HK2SSTR4 | |
| Hydrochloric Acid SCHEMBL29777443 | 0.77 | PYGB (0.39) | PYGBHK1HK2ALDH1A1SLC5A1 | |
| Hydrochloric Acid SCHEMBL21058387 | 0.77 | PYGB (0.39) | PYGBHK1HK2ALDH1A1SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | SLC2A1 34/4885PYGB 760/4885ACACB 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.